Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record.

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors

Hunold, Andrea, Weddeling, Nicole, Paulussen, Michael, Ranft, Andreas, Liebscher, Caren, Jürgens, Herbert · 2006 · Pediatric Blood & Cancer

Abstract

Background: The prognosis of Ewing tumor (ET) patients has significantly improved to cure rates approximating 70%. The prognosis in relapse, however, is poor. Promising response rates have recently been reported for the combination of topotecan (TOPO) and cyclophosphamide (CYC) encouraging wider application of this combination in patients with relapsed ETs. This report summarizes the experience of patients treated with TOPO/CYC for recurrent or refractory disease within the German ET trials. Procedure: Fifty‐four patients aged 3.2–49.5 (median: 17.4) years received TOPO (0.75 mg/m 2/day, days 1–5) and CYC (250 mg/m 2/day, days 1–5) following first (40) or second (6) relapse or progression under first‐line therapy (8). Results: A median of 3 (range: 1–11) TOPO/CYC courses were given. Sixteen patients (32.6%) showed partial response (PR), 13/49 (26.5%) had stable disease (SD), 14/49 (28.6%) progressed, 2/49 (4.1%) showed a mixed response (MR). In 4 patients response was not documented, 5/54 patients with complete initial resection at the diagnosis of relapse were excluded from the response analysis. At completion of relapse therapy, 24/54 patients had entered complete (19) or partial (5) remission, 2 had SD, 26 showed progression, information was unavailable in 2 patients. Of the 19 relapse patients achieving complete response (CR), 10 maintained remission (52.6%). At the time of evaluation, after a median follow‐up for survivors of 23.1 (range: 7.8–59.8) months from the event prompting TOPO/CYC treatment, 14/54 patients (25.9%) were in continuous complete (13) or partial (1) remission. Overall survival (OAS) after 1 year was 0.61 (95%‐CI 0.47–0.74). Conclusion: TOPO/CYC is active in relapsed ETs and warrants further evaluation. Pediatric Blood Cancer 2006;47:795–800. © 2006 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.20719

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
Hunold, A., Weddeling, N., Paulussen, M., Ranft, A., Liebscher, C., & Jürgens, H.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2006-01-12
Volume
47
Issue
6
Pages
795-800
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W2062845584
Cited by
168
References
0
FWCI
2.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. https://app.cochat.ai/papers/10.1002/pbc.20719
The paper
Hunold, A., Weddeling, N., Paulussen, M., Ranft, A., Liebscher, C., & Jürgens, H. (2006). Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.20719

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.